Photos: 2025 James Beard Restaurant and Chef Awards
Photos from the 2025 James Beard Restaurant and Chef Awards at the Lyric Opera House on June 16, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fibre2Fashion
22 minutes ago
- Fibre2Fashion
Louis Vuitton most counterfeited luxury brand: Entrupy report
Louis Vuitton is the most counterfeited luxury brand, according to the new 'State of the Fake' report from Entrupy, which found the brand accounted for 32.76 per cent of all its submissions for luxury goods. It was followed by Gucci (13.6 per cent), Chanel (13.4 per cent), Prada (9.8 per cent) and Dior (4.6 per cent). Prada was the second most counterfeited luxury brand regarding handbags, with 14.42 per cent of all Prada bags scanned by Entrupy being flagged as 'unidentified', i.e., a fake. Louis Vuitton is the most counterfeited luxury brand, said a report from Entrupy, which found the brand accounted for 32.76 per cent of all its luxury goods submissions. There is a growing sophistication in counterfeits, especially across high-volume and high-demand items. China and Hong Kong still dominate supply, with 3 per cent of counterfeit purchases being enabled by chatbots. Fake Gucci handbags worth $12,190,340 were submitted to the US-based artificial intelligence (AI)-powered authentication technology provider for verification in 2024, with Chanel accounting for the highest total dollar value with a total of $500,470,067 in counterfeit goods detected. The data shows a growing sophistication in counterfeits, especially across high-volume and high-demand items. French brand Goyard maintained its position as one of the most counterfeited brands by volume, with 18.4 per cent of its St. Louis Totes identified as fakes. The top five brands with an elevated risk of fakes were Goyard, Prada, Givenchy, Loewe and Saint Laurent. The Americas accounted for 47 per cent of all Entrupy submissions, with the Asia-Pacific accounting for 42 per cent and Europe and the Middle East accounting for 11 per cent. The report also named Louis Vuitton as the most frequently counterfeited brand in the United States, with the total value of authentic products verified by Entrupy reaching $640 million, compared to $61 million worth of 'unidentified' items. It is the most frequently counterfeited brand in Canada, Mexico, Taiwan, the United Kingdom, Germany and Indonesia as well. Prada was the most faked brand in Japan, while Saint Laurent was the most faked brand in Italy. Counterfeits now use block chain and cryptocurrency to hide operations and reinvest profits through legitimate businesses, the report noted. China and Hong Kong still dominate supply. Over 30 per cent of counterfeit goods seized at European borders originated from China and Hong Kong. Three per cent of counterfeit purchases are now enabled by chatbots. Fibre2Fashion News Desk (DS)
Daily Mail
23 minutes ago
- Daily Mail
Viktor Gyokeres is 'furious with Sporting Lisbon for blocking his move to Arsenal' as transfer saga turns ugly
Viktor Gyokeres is reportedly fuming with Sporting Lisbon for holding up his departure from the club this summer. The Swedish striker is one of the most in-demand strikers in Europe after flourishing in Portugal over the past two seasons, and had expected to get a transfer to the Premier League. Gyokeres prefers a move to Arsenal over Manchester United, but his price-tag has become a major stumbling block for any deal. It is understood that Gyokeres believes he reached a gentleman's agreement with Sporting last summer that would see the club accept a fee in the region of €70m (£60m) including add-ons at the end of the season. However, Sporting are now trying to hold out for a significantly higher fee - with Gyokeres having a €100m (£84m) release clause in his contract, and club president Frederico Varandas has accused Gyokeres' team of trying to 'blackmail' the Portuguese giants. Gyokeres has reportedly threatened to go on strike after vowing to 'speak at the right time', and, according to Portuguese outlet A Bola, he is 'very upset' with Sporting's current stance and has made his feelings clear to the club's hierarchy. Their report claims five clubs are interested in signing Gyokeres, with Atletico Madrid, Juventus and Saudi Arabian team Al-Ahli joining Arsenal and United in monitoring the 27-year-old's situation. Gyokeres would also welcome interest from Manchester City and Liverpool, while he is open to a move to Real Madrid, Barcelona, PSG or Bayern Munich. But Sporting are adamant that they won't let their star striker leave for a fee that falls below their asking price. Varandas claimed last week that Sporting will not demand £84m for Gyokeres, but also stated that allowing the forward to depart for £60m is also off the table as a war of words broke out. 'Sporting will not demand the release clause, but they should know me better by now,' Varandas said. 'Threats, blackmail and insults don't work with me. 'I can guarantee one thing: Viktor Gyokeres will not leave for €60m + €10m. He won't leave because I never allowed it, and the game his agent is playing will only make the situation worse.' Varandas has denied a gentleman's agreement was ever in place as the transfer saga continues to turn ugly. Gyokeres may now be concerned that he could miss out on a move to Arsenal, with the Gunners also closely tracking several other options to bolster their frontline. The north London club have shown interest in RB Leipzig's Benjamin Sesko, while Alexander Isak, Julian Alvarez and Ollie Watkins are also believed to be on their radar as potential alternatives. But Gyokeres could be the standout candidate to fill the No 9 role after scoring 97 goals in 102 appearances for Sporting. His goals secured a domestic double for the club last term, and Arsenal may view him as the missing piece of the jigsaw as they look to end their trophy drought under Mikel Arteta next season.
Business Upturn
23 minutes ago
- Business Upturn
Boehringer Ingelheim Launches Next Generation Innovative Three-in-One Poultry Vaccine in India
Mumbai, Maharashtra, India: New single-dose vaccine offers broad protection against three major poultry diseases, improving bird health and easing the operational burden on farms. Strengthens poultry portfolio in India with two launches in th e past one year. Boehringer Ingelheim, a global leader in animal health, has announced the launch of its latest poultry vaccine in India—a single-dose, next-generation solution that provides protection against Bursal, Newcastle, and Marek's disease. This innovative vaccine is designed to address the practical challenges faced by poultry farmers in India, offering early, reliable, and long-lasting immunity with just one administration at the hatchery. With poultry playing a vital role in India's food supply and rural economy, disease outbreaks remain a serious threat to both productivity and profitability. This new vaccine offers a streamlined approach to disease prevention by reducing the need for multiple field vaccinations, lowering labor requirements, and minimizing bird handling stress—all while maintaining strong disease control across production systems. Dr. Vinod Gopal, Country Head-Animal Health, Boehringer Ingelheim India, emphasized the company's focus on local needs, 'We understand the pressure Indian poultry farmers face—from disease control to operational efficiency. This vaccine reflects our commitment to bringing science-led, farmer-focused innovations to the market. By combining protection into a single dose, we are helping farmers enhance productivity, improve bird welfare, and build more resilient operations.' Dr. K. S. Prajapati, Former HOD, Dept. of Vet. Pathology, College of Vet. Science, AAU, Anand commented on the significance of this advancement, 'Farmers need solutions that are both effective and practical. The evolving disease landscape demands smarter protection strategies. A vaccine that offers early, combined immunity against three major diseases is a valuable tool that helps farmers secure their flocks and reduce reliance on antibiotics.' The vaccine is suitable for broilers, layers, and breeders, and can be administered either in ovo or via subcutaneous injection at the hatchery. Boehringer Ingelheim Animal Health Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at About Boehringer Ingelheim Advertisement Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering innovative products in Human Pharma and Animal Health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. Learn more at Submit your press release Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
